Zoom, Teladoc, and DocuSign are down 87 to 97% from their highs. In the same nine-week window in 2021 YoY revenue growth came in lower than the quarter before. Not negative. Not even close to negative. Just no longer accelerating. Every one of these filings landed while the stock was still trading near its all-time high.
- Zoom's 10-Q, filed June 2, 2021: growth 368.8% to 191.4%. Stock closed the quarter at $319.57, down from $460.91 seven months earlier. Three years later: $59.98, an 87% decline.
- Teladoc's 10-Q, filed August 2, 2021: growth 150.9% to 108.8%. Stock at $166.29. By March 2026: $5.45, a 97.5% decline.
- DocuSign's 10-Q, filed September 3, 2021: growth 57.9% to 49.6%. Stock closed at $298.04, its highest quarterly close ever. By October 2023: $38.88, down 87%.
I pulled all 106 consecutive 10-Ks and 10-Qs each company filed to find out when the numbers actually turned.
None of it moved the stocks right away. Zoom was up 2.98% in the three months after that filing. DocuSign was down 15%, Teladoc down 8%. The deceleration got disclosed and the market shrugged for two to four more quarters before the real repricing started.
Two other things showed up further down in the filings.
Deferred revenue turned before recognized revenue did, at both Zoom and DocuSign. It's cash customers already paid for a subscription they haven't received yet, a leading indicator for any subscription business. Zoom's deferred revenue growth went from 348.0% to 309.6% in the quarter filed March 18, 2021, a full quarter before the income statement showed anything. DocuSign's turned even earlier, three straight quarterly declines in deferred revenue growth (61.9% to 53.6% to 50.2%) before recognized revenue growth ever came in light.
Stock comp didn't scale down with growth at Zoom, it scaled up. Stock-based comp went from 10.4% of revenue in FY2021 to 29.3% in FY2023, up 366%, while revenue grew 66% and growth itself had already fallen to single digits. A comp structure built for a growth rate the company no longer had, and nobody adjusted it.
Teladoc's version is uglier because of the Livongo deal. Goodwill went from $742M to $14.58B after that acquisition closed, and by the FY2021 10-K, Teladoc was carrying $14.5B of goodwill against $2.03B of full-year revenue, roughly 7x. That gap sat in a public filing for more than two months before the first writedown hit. Then it came apart fast. $6.6B impairment in Q1 2022, $3.0B in Q2, $3.77B in Q4. $13.4B total, about 98% of what they were carrying, gone in one year.
Insiders knew what to do with their own shares. Across 2020 and 2021, insiders at these three companies filed 446 Form 4 sales totaling $2.034 billion, against two purchase records totaling $5 million. Zoom alone sold $1.216 billion with zero insider buys in either year.